These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

339 related items for PubMed ID: 16117995

  • 41. Use of valsartan in post-myocardial infarction and heart failure patients.
    Liu PP, Maggioni A, Velazquez EJ.
    J Renin Angiotensin Aldosterone Syst; 2006 Jun; 7 Suppl 1():S19-22. PubMed ID: 16986231
    [Abstract] [Full Text] [Related]

  • 42. Augmented short- and long-term hemodynamic and hormonal effects of an angiotensin receptor blocker added to angiotensin converting enzyme inhibitor therapy in patients with heart failure. Vasodilator Heart Failure Trial (V-HeFT) Study Group.
    Baruch L, Anand I, Cohen IS, Ziesche S, Judd D, Cohn JN.
    Circulation; 1999 May 25; 99(20):2658-64. PubMed ID: 10338459
    [Abstract] [Full Text] [Related]

  • 43. [Epidemiologic evaluation of cardiac decompensation and its impact on health costs].
    Bilora F, Vettore G, Saccaro G, Barbata A, Dei Rossi C, Petrobelli F.
    Minerva Cardioangiol; 1998 May 25; 46(7-8):235-9. PubMed ID: 9973786
    [Abstract] [Full Text] [Related]

  • 44. Drug copayment and adherence in chronic heart failure: effect on cost and outcomes.
    Cole JA, Norman H, Weatherby LB, Walker AM.
    Pharmacotherapy; 2006 Aug 25; 26(8):1157-64. PubMed ID: 16863491
    [Abstract] [Full Text] [Related]

  • 45. Outcomes in subgroups of hypertensive patients treated with regimens based on valsartan and amlodipine: An analysis of findings from the VALUE trial.
    Zanchetti A, Julius S, Kjeldsen S, McInnes GT, Hua T, Weber M, Laragh JH, Plat F, Battegay E, Calvo-Vargas C, Cieśliński A, Degaute JP, Holwerda NJ, Kobalava J, Pedersen OL, Rudyatmoko FP, Siamopoulos KC, Störset O.
    J Hypertens; 2006 Nov 25; 24(11):2163-8. PubMed ID: 17053536
    [Abstract] [Full Text] [Related]

  • 46. Clinical, neurohormonal, and inflammatory markers and overall prognostic role of chronic obstructive pulmonary disease in patients with heart failure: data from the Val-HeFT heart failure trial.
    Staszewsky L, Wong M, Masson S, Barlera S, Carretta E, Maggioni AP, Anand IS, Cohn JN, Tognoni G, Latini R, Valsartan Heart Failure Trial Investigators.
    J Card Fail; 2007 Dec 25; 13(10):797-804. PubMed ID: 18068611
    [Abstract] [Full Text] [Related]

  • 47. Reducing costs and improving hypertension management.
    Stankus V, Hemmelgarn B, Campbell NR, Chen G, McAlister FA, Tsuyuki RT.
    Can J Clin Pharmacol; 2009 Dec 25; 16(1):e151-5. PubMed ID: 19193969
    [Abstract] [Full Text] [Related]

  • 48. Cost-effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in newly diagnosed type 2 diabetes in Germany.
    Adarkwah CC, Gandjour A.
    Int J Technol Assess Health Care; 2010 Jan 25; 26(1):62-70. PubMed ID: 20059782
    [Abstract] [Full Text] [Related]

  • 49. Role of combination therapy in the treatment of hypertension: focus on valsartan plus amlodipine.
    Ferri C, Croce G, Desideri G.
    Adv Ther; 2008 Apr 25; 25(4):300-20. PubMed ID: 18449492
    [Abstract] [Full Text] [Related]

  • 50. [Review of randomized trials of angiotensin receptor blockers in the treatment of patients with congestive heart failure].
    Rakugi H, Ogihara T.
    Nihon Rinsho; 2001 Oct 25; 59(10):2051-61. PubMed ID: 11676153
    [Abstract] [Full Text] [Related]

  • 51. Comparison of treatment benefit and outcome in women versus men with chronic heart failure (from the Valsartan Heart Failure Trial).
    Majahalme SK, Baruch L, Aknay N, Goedel-Meinen L, Hofmann M, Hester A, Prescott MF, Feliciano N, Val-HeFT Study Investigators.
    Am J Cardiol; 2005 Feb 15; 95(4):529-32. PubMed ID: 15695147
    [Abstract] [Full Text] [Related]

  • 52. Determining the most appropriate components for a composite clinical trial outcome.
    Bethel MA, Holman R, Haffner SM, Califf RM, Huntsman-Labed A, Hua TA, McMurray J.
    Am Heart J; 2008 Oct 15; 156(4):633-40. PubMed ID: 18926145
    [Abstract] [Full Text] [Related]

  • 53. Should angiotensin receptor blockers be added to angiotensin-converting enzyme inhibitors in the treatment of heart failure?
    Ghanem FA, Movahed A.
    Rev Cardiovasc Med; 2005 Oct 15; 6(4):206-13. PubMed ID: 16379016
    [Abstract] [Full Text] [Related]

  • 54. Blocking the renin-angiotensin system: dual- versus mono-therapy.
    Ravandi A, Teo KK.
    Expert Rev Cardiovasc Ther; 2009 Jun 15; 7(6):667-74. PubMed ID: 19505282
    [Abstract] [Full Text] [Related]

  • 55. Impact of rosuvastatin use on costs and outcomes in patients at high risk for cardiovascular disease in US managed care and medicare populations: A data analysis.
    Huse DM, Song X, Ozminkowski RJ, Maguire J, Williams SA, Borok GM, McDonough K.
    Clin Ther; 2006 Sep 15; 28(9):1425-42. PubMed ID: 17062315
    [Abstract] [Full Text] [Related]

  • 56. Baseline and serial measurements of galectin-3 in patients with heart failure: relationship to prognosis and effect of treatment with valsartan in the Val-HeFT.
    Anand IS, Rector TS, Kuskowski M, Adourian A, Muntendam P, Cohn JN.
    Eur J Heart Fail; 2013 May 15; 15(5):511-8. PubMed ID: 23291728
    [Abstract] [Full Text] [Related]

  • 57. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure.
    Tepper D.
    Congest Heart Fail; 2002 May 15; 8(1):57-8. PubMed ID: 11821630
    [No Abstract] [Full Text] [Related]

  • 58. Serial measurement of growth-differentiation factor-15 in heart failure: relation to disease severity and prognosis in the Valsartan Heart Failure Trial.
    Anand IS, Kempf T, Rector TS, Tapken H, Allhoff T, Jantzen F, Kuskowski M, Cohn JN, Drexler H, Wollert KC.
    Circulation; 2010 Oct 05; 122(14):1387-95. PubMed ID: 20855664
    [Abstract] [Full Text] [Related]

  • 59. Dual renin angiotensin system blockade in patients with acute myocardial infarction and preserved left ventricular systolic function.
    Suşan M, Petrescu L, Riviş AI, Suşan RM, Burghină D, Dan R, Cozma D, Drăgulescu SI.
    Rom J Intern Med; 2005 Oct 05; 43(3-4):187-98. PubMed ID: 16812979
    [Abstract] [Full Text] [Related]

  • 60. Markov modeling analysis of health and economic outcomes of therapy with valsartan versus amlodipine in patients with type 2 diabetes and microalbuminuria.
    Smith DG, Nguyen AB, Peak CN, Frech FH.
    J Manag Care Pharm; 2004 Oct 05; 10(1):26-32. PubMed ID: 14720103
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.